A phase I/II trial on combining radiation with immunotherapy for breast cancer recurrence found 79% of treated skin tumors responded when imiquimod cream was paired with targeted radiation.
This post covers a mouse model study exploring triple negative breast cancer immunotherapy options through a three-drug approach targeting T cell exhaustion in the tumor microenvironment.
Can nanotechnology reduce breast cancer drug side effects? This preclinical study found a dual-drug nanoparticle system cut tumor growth by 72.93% in mice.